Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27885856 | 0.76 | KDM4E (0.37) | KDM4EKDM5CPHF8KDM2ATDP1 | |
| SCHEMBL14510764 | 0.74 | TDP1 (0.31) | KDM4ETDP1EYA2APPACE | |
| SCHEMBL8199567 | 0.73 | — | — | |
| Bromide SCHEMBL7533244 | 0.71 | TDP1 (0.36) | KDM4ETDP1EYA2APPACE | |
| Bicarbonate SCHEMBL5014541 | 0.70 | CYP1A2 (0.33) | LMNATSHR | |
| Nitrilotriacetic Acid SCHEMBL508415 | 0.70 | TDP1 (0.46) | KDM4EKDM5CPHF8KDM2ATDP1 | |
| SCHEMBL7713378 | 0.69 | — | — | |
| SCHEMBL8617978 | 0.69 | NOS3 (0.44) | ALOX15BLMPMP22 | |
| SCHEMBL2953649 | 0.69 | — | — | |
| SCHEMBL8043996 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | claimed |
| EP-0793646-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016031-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-6288124-B1 | Methods of inhibiting undesirable cell growth using an aminoguanidine compound | KADDURAH-DAOUK RIMA (US) | 2001-09-11 | — | — | US | disclosed |
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6169115-B1 | SUBSTRATES OR SUBSTRATE ANALOGS FOR CREATINE KINASE; | KADDURAH-DAOUK RIMA (US) | 2001-01-02 | — | — | US | disclosed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1001758-A1 | USE OF A DRUG CAPABLE OF MODULATING THE REGULATION OF UPC-2 AND METHOD FOR SCREENING FOR POTENTIAL DRUGS AGAINST OBESITY | Pharmacia & Upjohn AB (SE) | 2000-05-24 | — | — | EP | disclosed |
| US-6001578-A | DEVELOPING POTENTIAL DRUGS FOR TREATING OBESITY, METABOLIC SYNDROME OR NON-INSULIN DEPENDENT DIABETES MELLITUS; CONTACTING CELLS EXPRESSING FAT PROTEIN WITH MODULATING DRUG, CULTURING CELLS, DETECTING GENE EXPRESSION INDICATORS | PHARMACIA & UPJOHN AB (SE) | 1999-12-14 | — | — | US | disclosed |
| WO-1999000123-A1 | USE OF A DRUG CAPABLE OF MODULATING THE REGULATION OF UPC-2 AND METHOD FOR SCREENING FOR POTENTIAL DRUGS AGAINST OBESITY | PHARMACIA & UPJOHN AB (SE) | 1999-01-07 | — | — | WO | disclosed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | KDM4E 3385/4885KDM5C 3250/4885PHF8 4283/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | KDM4E 1519/4885KDM5C 2304/4885PHF8 3181/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | KDM4E 2996/4885KDM5C 3148/4885PHF8 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.